In the LIBRETTO-001 phase I/II trial, selpercatinib demonstrated unprecedented efficacy and safety in treating various RET-altered advanced malignancies, including MTC, with greater disease response, progression-free survival and fewer toxicities compared to results with multi-kinase inhibitors in other trials (5). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.